Quest Diagnostics (DGX) Tops Q2 EPS by 12c; Raises Outlook
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Price: $237.14 -0.94%
EPS Growth %: +10.0%
Financial Fact:
Other (expense) income, net: 4M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +10.0%
Financial Fact:
Other (expense) income, net: 4M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.36, $0.12 better than the analyst estimate of $2.24. Revenue for the quarter came in at $2.45 billion versus the consensus estimate of $2.32 billion.
GUIDANCE:
Quest Diagnostics sees FY2022 EPS of $9.55-$9.95, versus the consensus of $9.33.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
